A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Zozaya, Néboa (Universidad de Las Palmas de Gran Canaria)
Arrizubieta Basterrechea, M.I. (Hospital de Galdakao (Usansolo, Biscaia))
Bollo, E. (Complejo Asistencial Universitario de León)
Castellvi, Ivan (Institut d'Investigació Biomèdica Sant Pau)
Espín, J. (Andalusian School of Public Health)
Ortego, N. (Hospital Universitario San Cecilio (Granada))
Poveda-Andrés, J.L. (Hospital Universitari i Politècnic La Fe (València))
Rodríguez Portal, J.A. (Centro de Investigación Biomédica en Red - Enfermedades Respiratorias (CIBERES))
Rivero, A. (Bioregión de Salud y Bienestar (BioMad))
Marcos-Rodríguez, J.A. (Hospital Universitario Virgen Macarena)
Verde, L. (Integrated Health Area)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0. 50 ± 0. 16, on a scale from -1 to 1) and SSc-ILD (0. 40 ± 0. 12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0. 06-0. 07), given its proven clinical efficacy (0. 05-0. 06), slight improvements in patient-reported outcomes (0. 01-0. 02), and similar safety profile than placebo (-0. 04-0. 00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Interstitial lung diseases ; Multi-criteria decision analysis ; Pulmonary fibrosis ; Systemic sclerosis
Publicat a:	International Journal of Technology Assessment in Health Care, Vol. 38 Núm. 1 (january 2022) , p. e64, ISSN 1471-6348

DOI: 10.1017/S0266462322000459
PMID: 35912833

10 p, 737.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats